Binh Ba Ngo: career, board roles and research publications
A sourced career record for Binh Ba Ngo (Ngô Bá Bình), covering his company and board roles and peer-reviewed research on probiotic Bacillus subtilis.
Binh Ba Ngo (Ngô Bá Bình) is the founder and owner of Inogen Pty Ltd. This page brings together his background, board roles, research and the news about him.
01Founder & Leadership

AU$122Mbusiness value created
Founder and Owner, Inogen Pty Ltd
Twenty-six years building diagnostics companies. Two sold to listed global groups. Now developing Australian-branded diagnostic kits in Queensland.
Binh Ba Ngo is a serial entrepreneur in molecular diagnostics, a field where scientific, regulatory and clinical barriers meet. He has co-founded eight companies. Two were acquired by listed global groups, Gentis by Eurofins Scientific and Biomedic by DKSH, and in both cases he was retained through and beyond completion. Acquirers rarely keep founders.
His method is repeatable. He identifies a diagnostic capability proven internationally but missing from the local market, then builds everything it needs to become standard practice: the technology, regulatory approval, laboratory, team and an economic model the health system can sustain. Five categories of medical testing became routine in Vietnam's leading hospitals this way.
He combines three capabilities that rarely sit in one person: scientific direction as a molecular biologist, full profit and loss responsibility at group scale, and personal leadership of both company sales. Through Inogen, he is moving product development, testing and certification to Australia, creating Australian-branded kits priced below imports and built for international markets.
SELECTED ACHIEVEMENTS
02Career
Roles and dates as listed on his LinkedIn profile, with his role at Tâm Việt as confirmed by his family.
September 2022 to present
Phacogen Group, Hanoi
2022 to present
Eramic Technology Era JSC
2021 to present
Phu Thai Pharmaceutical JSC
From August 2025
Inogen Pty Ltd, Queensland
October 2024 to September 2026
Biomedic Joint Stock Company, Hanoi
2014 to March 2025
Tâm Việt Medical Equipment and Science Co. Ltd, Hanoi
2010 to 2025
Gentis Joint Stock Company, Hanoi
03Selected moments
Binh Ba Ngo's work spans company leadership, scientific exchange and the development of diagnostic businesses.



04News and milestones
Dated records of his board roles, research publications and the founding of Inogen, each with its source.
A sourced career record for Binh Ba Ngo (Ngô Bá Bình), covering his company and board roles and peer-reviewed research on probiotic Bacillus subtilis.
The Vietnam Journal of Science and Technology published a safety evaluation of Bacillus subtilis Eramic 26, co-authored by Binh Ba Ngo (Ngô Bá Bình), on 25 February 2026.
Microbiology Resource Announcements published the draft genome of Bacillus subtilis Eramic25 on 9 October 2025; Binh Ba Ngo (Ngô Bá Bình) supervised the project.
Inogen Pty Ltd, founded by Binh Ba Ngo (Ngô Bá Bình), is an Australian private company; its ABN 73 691 280 467 has been active since 24 September 2025.
A study co-authored by Binh Ba Ngo (Ngô Bá Bình) on the in vitro safety of the probiotic strain Bacillus subtilis Eramic 25 was published on 14 May 2025.
GENTIS celebrated its 13th anniversary in Ha Long on 25 and 26 October 2023; board member Binh Ba Ngo (Ngô Bá Bình) attended.
On 9 February 2022 Binh Ba Ngo (Ngô Bá Bình) was elected to the Board of Directors of GENTIS as the company joined the Eurofins Scientific group.
05Research & Publications
Peer-reviewed research co-authored by Ngô Bá Bình, with a link to each published paper.
06More about Binh Ba Ngo
Independent pages and records that name Binh Ba Ngo (Ngô Bá Bình), including news coverage, company records and his published research.
Full profile and sources Research & Publications ORCID record Google Scholar profile
Our team answers laboratory and procurement enquiries in English and Vietnamese.